Updated:
Fate Therapeutics
Fate Therapeutics was founded in 2007 by a group of stem-cell biologists including Rudolf Jaenisch, Sheng Ding, and Randall Moon, emerging from the...
Fate Therapeutics
Fate Therapeutics was founded in 2007 by a group of stem-cell biologists including Rudolf Jaenisch, Sheng Ding, and Randall Moon, emerging from the convergence of induced pluripotent stem cell technology and immunology. The company went public in 2013 and established its clinical focus on off-the-shelf, iPSC-derived natural killer and T-cell immunotherapies for cancer and autoimmune disorders. Unlike patient-specific CAR-T therapies, Fate's platform engineers a clonal master cell line that can be expanded into unlimited homogeneous doses, a process designed to reduce manufacturing costs and treatment turnaround time. The firm's pipeline spans clinical-stage assets targeting hematologic malignancies and solid tumors. Its lead program, FT576, is a multi-antigen-targeted CAR NK cell therapy evaluated in combination with CD38-targeting antibodies for multiple myeloma. Fate also advanced FT522, a CD19-targeted CAR NK cell incorporating proprietary allo-immune resistance technology, into early clinical studies for B-cell lymphoma. The platform extends beyond oncology — in 2024, Fate initiated a proof-of-concept study using its iPSC-derived CAR T-cells for systemic lupus erythematosus, signaling an intent to address autoimmune disease. The company's operations are based in San Diego, California, and its cell product manufacturing is conducted in a dedicated internal facility designed to scale iPSC-derived therapies under current good manufacturing practices. Fate has historically operated through partnerships and public market financing. In 2020, the firm entered a collaboration with Janssen, a Johnson & Johnson subsidiary, under which Janssen received options to license certain cell-based cancer immunotherapies (per the firm, 2020). The partnership concluded in 2023 with Fate retaining full rights to its pipeline programs. As of early 2025, the company underwent a leadership transition — founder Scott Wolchko stepped down as CEO, and Bob Valamehr, previously head of R&D, assumed the role of President and CEO (per the firm, January 2025). The company's board includes former senior executives from Amgen, Celgene, and Kite Pharma. Fate's structural differentiator lies in its manufacturing architecture. The company controls a proprietary, vertically integrated process that combines iPSC reprogramming, genetic engineering, and clonal selection to produce a single master cell bank capable of yielding thousands of therapeutic doses. This contrasts with autologous CAR-T therapy, where each patient receives a uniquely manufactured product. The firm's strategy hinges on demonstrating that mass-manufactured, donor-derived cell therapies can match the durability of personalized treatments while reducing per-patient cost and logistical burden.
General information
Firm type
Asset Manager
Year founded
2007
AUM
Undisclosed
Location
Region
North America
Country
United States
City
San Diego
Corporate office
San Diego, CA, United States
Principals
Bob Valamehr
President and Chief Executive Officer
Sector focus
Frequently asked questions
What makes Fate Therapeutics' iPSC platform structurally different from other cell therapy companies?
Fate uses a clonal master cell line derived from induced pluripotent stem cells, which is genetically engineered once and then expanded into unlimited batches of natural killer or T-cell therapies. This contrasts with autologous CAR-T approaches that require extracting, engineering, and reinfusing a patient's own cells. The iPSC model aims for off-the-shelf consistency, simplified logistics, and lower per-dose manufacturing cost.
What is the status of Fate's clinical pipeline in autoimmune disease?
In 2024, Fate Therapeutics initiated a Phase 1 clinical trial evaluating its iPSC-derived CD19-targeted CAR T-cell product in adults with systemic lupus erythematosus. This marks the company's first foray beyond oncology and signals a thesis that repurposing cell-based immunotherapies could achieve deeper B-cell depletion than antibody-based treatments in autoimmune conditions.
Who runs investment and capital allocation decisions at Fate Therapeutics?
Fate Therapeutics is a publicly traded clinical-stage biotech, not an investment firm, so capital allocation is overseen by the President and CEO, Bob Valamehr, together with the board of directors. Day-to-day financing and partnership decisions are managed by the executive leadership team.
Does Fate Therapeutics operate a family office or deploy third-party capital?
No. Fate Therapeutics is a publicly listed biotechnology company (NASDAQ: FATE) focused on developing cell therapies. It is not a family office and does not manage third-party investment vehicles. Its funding comes from public equity markets, strategic partnerships, and historically from collaborations like the now-concluded Janssen agreement.
What happened to Fate's partnership with Johnson & Johnson?
In 2020, Fate Therapeutics entered a broad collaboration and option agreement with Janssen, a J&J subsidiary, granting Janssen rights to license certain iPSC-derived cancer immunotherapy programs. The partnership ended in early 2023, with Fate retaining full ownership and control of all pipeline assets, including those previously subject to the collaboration.
Who founded Fate Therapeutics and what was their original scientific mandate?
Fate was founded in 2007 by stem-cell researchers including Rudolf Jaenisch, Sheng Ding, and Randall Moon. The original mandate centered on harnessing developmental biology and induced pluripotent stem cell technology to create cell-based therapeutics, a focus that gradually narrowed to iPSC-derived immunotherapies for cancer and autoimmune disease.
What is Fate Therapeutics' relationship to CAR-T cell therapy?
Fate does not develop patient-specific CAR-T therapies. Instead, it engineers iPSC-derived CAR NK and CAR T-cell lines that are manufactured in bulk and administered as off-the-shelf treatments. This positions Fate as a competitor to autologous CAR-T companies rather than a participant in that specific manufacturing model.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: